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a b s t r a c t
Calciﬁc aortic valve disease (CAVD) is themost common valvular heart disease in the elderly.
As life expectancy increases, prevalence of CAVD is expected to rise. CAVD is characterized
by progressive dystrophic calciﬁcation of aortic cusps. In the initial stages, the pathogenesis
is similar to atherosclerosis, characterized by basement membrane disruption, inﬂamma-
tion, cell inﬁltration, lipid deposition, and calciﬁcation. Presence of osteopontin in calciﬁed
aortic valves suggests pathological calciﬁcation and bone formation in these calciﬁed valves.
Historical, experimental, genetic, and clinical evidences suggest that CAVD and atheroscle-
rosis share the same pathological sequences with common risk factors. Understanding the
two faces of atherosclerosis, the vascular and valvular, will help us to prevent progression of
aortic sclerosis to aortic stenosis, by controlling modiﬁable risk factors and by initiating
statin therapy in them. However, the knowledge about these preventivemeasures and drugs
is scanty. In this review article, an attempt is made to unfurl the relation between athero-
sclerosis and CAVD.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.1. IntroductionCalciﬁc aortic valve disease (CAVD) is the major cause for
surgical valve replacement in western countries. Rheumatic
fever haswaned as cause of aortic stenosis (AS), and CAVDhas
become the prime cause of AS even in developing countries.
The perception that calciﬁc AS is the result of aging and wear
and tear1 of aortic valve is changing. There are similarities
between the plaque of coronary atherosclerosis and initial
lesions of CAVD,with presence of similar risk factors for both.2
Monckeberg3 described the dystrophic calciﬁcation of the* Corresponding author.
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0019-4832/# 2015 Cardiological Society of India. Published by Elsevieraortic valve in 1904 as cause of nonrheumatic calciﬁc AS. This
article attempts to discuss the insights to debate whether
CAVD is another face of atherosclerosis.2. The risk factors for vascular atherosclerosis
and CAVD
Hypertension, smoking, diabetes mellitus, elevated cholester-
ol, and male gender have been identiﬁed as the risk factors
shared by CAVD and atherosclerosis, and a concept of
atheromatous valvulopathy thus evolved.4 An active biologicalB.V. All rights reserved.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 5 0 3 – 5 0 6504process similar to atherosclerosis type of pathophysiology
involving oxidative stress, inﬂammation, and endothelial
dysfunction in aortic valves was noted in patients with
hypercholesterolemia. Hemodynamic stress, genetic dysregu-
lation, and oxidative stress lead to active inﬂammatory
process resulting in severe calciﬁc AS. Conventional treatment
of CAVD with severe AS is aortic valve replacement. But with
apparent similarities between CAVD and atherosclerosis,
pharmacotherapy, designed to retard the process of athero-
sclerosis, can be considered to slow progression of CAVD if
therapy is initiated early.
2.1. Histological evidences
Pomerance1 and Roberts5 described calciﬁcation of the aortic
cusps that was preceded by lipid deposition and postulated
that CAVD shared the same etiology as coronary atheroscle-
rosis. Otto et al.2 and others6 have also delineated the
histological features of CAVD. Characteristically, thickening
and calciﬁcation of aortic valves are seen only on the aortic
side on gross inspection. Microscopically, diseased aortic
leaﬂets have disrupted endothelium on the aortic side alone
but not on ventricular side, and the disease progresses through
stages of sclerosis and stenosis. There is subendothelial
accumulation of intra- and extracellular lipids and lipopro-
teins. Chronic inﬂammatory cell inﬁltration made up of foam
cells, nonfoam cell macrophages, and 'T' lymphocytes has
been noted. The regions with lipoproteins are at the same
location as areas of calciﬁcation. From the subendocardial
region, these lesions extend to the central portion of the
leaﬂets called the ﬁbrosa and most often involve the base of
the leaﬂets. This process is similar to what occurs in vascular
atherosclerosis.7
2.2. Experimental evidences
Experimental models of atherosclerosis are important to
understand the disease process of CAVD if the risk factors
are common for both. Studies in mice and rabbits have proven
that hypercholesterolemia causes both atherosclerosis and
valve calciﬁcation. Early endothelial abnormalities in the
aortic valves have been described in experimental hypercho-
lesterolemia in rabbits.8 Three months of cholesterol diet
induced early mineralization and endothelial nitric oxide
synthase mediated modiﬁcation of the aortic valve. Six
months of cholesterol diet induced marked thickening and
calciﬁcation of the aortic valve leaﬂets with attenuation on
atorvastatin therapy.9 In experimental rabbit model, when the
effect of angiotensin-converting enzyme inhibitors (ACE) was
tested, inhibition of atherosclerotic process was noted.10
Drolet et al.11 have also shown that a high cholesterol diet
and vitamin D treatment resulted in development of AS in
rabbits.
2.3. Genetic evidences
The pathobiology of aortic valve calciﬁcation is closely linked
to genetic factors. The NOTCH I12 transcriptional factor
regulates osteogenic differentiation, as well as valve develop-
ment. Functional mutations in the gene may increaseosteoblast formation and calciﬁcation and alter structural
development of valve. Aortic valve cusps, which are under
constantmechanical stress, require constant cell turnover and
telomeric changes. Calciﬁcation is a distinguishing feature of
CAVD and Shetty et al.13 found that calciﬁed valve allografts
expressed bone-speciﬁc transcription factor cbfa-1, osteopon-
tin, and osteonectin, which were not found in normal valves.
The genotype in the genetic mouse model, which lacks the
gene for LDL receptor but expresses the receptor for human
apolipoprotein B-100, is known to be associated with human
atherogenic lipid abnormalities and induces valvular and
vascular atherosclerosis.14 The mechanism by which calciﬁ-
cation develops is activation and upregulation of the LDL
receptor 5 (Lrp5) pathway in vascular and valvular interstitial
cells. Elevated cholesterol induces a phenotypic switch to bone
forming cells within the valve leaﬂets.15 Matrix metallopro-
teinases, interleukin, transforming growth factor beta, purine
nucleotides, and tumor necrosis factor alpha have all been
identiﬁed as signaling pathways along with Lrp5 pathway in
the development and progression of vascular atherosclerosis
and bone formation. There is also increased expression of
elastolytic cathepsins S, K, and V and their inhibitor cystatin C
in the stenotic aortic valves.
2.4. Clinical evidences
New imaging modalities, like contrast-enhanced molecular
imaging as adjunct to cardiac magnetic resonance imaging
using nanoparticles, have been shown to penetrate athero-
sclerotic plaques and delineate the pathology involved in
CAVD better.16 Microcomputerized tomography is helpful to
assess mineral levels in explanted human heart valves.
Characteristic heavy calciﬁcation has been shown to occur
near the outer edges of each calciﬁed nodule found on the
valve as reported by Rajamannan et al.15 These new imaging
modalities, which characterize underlying pathological pro-
cesses, may help decide on appropriate treatment targets. It is
worthwhile considering randomized controlled trials with and
without statins in cases of bicuspid aortic valves to study the
progression of aortic stenosis in them.
Statins, by lowering lipid levels, as well as by pleiotropic
effects, downregulate expression of inﬂammatory cytokines
and thereby alter the inﬂammatory milieu in degenerative
heart valves. Retrospective clinical trials17 with statin therapy
have shown 50% reduction in the progression of CAVD.
However, prospective clinical trials such as SALTIRE18 (Scot-
tish Aortic Stenosis and Lipid Lowering Therapy) trial did not
show any positive result with high-dose atorvastatin in severe
AS. In SEAS study,19 the combination of Ezetemibe and
Simvastatin failed to alter clinical outcomes in 1800 patients
with AS. THE ASTRONOMER study20 (AS progression observa-
tion, measuring effects of rosuvastatin trial) showed that
despite favorable changes in lipid parameters and CRP,
progression of AS, as measured by peak aortic gradient, was
not altered. Treatment with rosuvastatin did not slow
progression of AS in the subgroup analysis based on AS
severity, age, and severity of calciﬁcation of aortic valve.
However, the RAAVE21 (Rosuvastatin affecting Aortic Valve
Endothelium) study demonstrated that rosuvastatin slowed
progression of CAVD.
Table 1 – Comparison of calcific aortic valve disease and
atherosclerosis.25
Calciﬁc aortic
valve disease
Atherosclerosis
i n d i a n h e a r t j o u rn a l 6 7 ( 2 0 1 5 ) 5 0 3 – 5 0 6 505The stage at which statin therapy is initiated matters.
Normalization of plasma lipid levels at early stages of AV
disease could reverse or halt progression of AS. If this is so,
why have prospective studies been negative? The possibilities
are:Histopathologic features
Lipoprotein accumulation ++++ ++++(1) S
Lipid oxidation ++++ ++++
Calciﬁcation +++++ ++
Inﬂammatory changes +++ ++++
Systemic inﬂammatory
markers
+ ++tatin treatment was initiated far too late in the course of
the disease, though mild and moderate AS patients were
included. Miller et al.22 showed that genetic switch for lipid
lowering was initiated early in the disease process even
before hemodynamic changes were noted.Chlamydophila pneumoniae + +(2) It
and other infectious
agentsis possible that only certain time periods of disease
development are susceptible to modulation by lipid
lowering drugs.Genetic polymorphisms ++ +++
Prominent cell type Fibroblast Smooth(3) Omusclether pharmacological tools to alter blood lipid proﬁles
may have a role in treatment of AS besides statins.(4) L
Clinical risk factors
Renal dysfunction ++++ ++++
Smoking +++ ++++
Hypertension ++ ++++
Elevated serum
lipoprotein levels
+++ ++++
Diabetes mellitus + +++
Endothelial dysfunction ++ ++++ipid accumulation may not be the only focal point of
disease pathogenesis.
Angiotensin-converting enzyme, angiotensin II (AT II), and
the proﬁbrotic AT I receptors are present in stenotic aortic
valves and their enzymatic activity is augmented in diseased
valves. This may cause the proﬁbrotic and proinﬂammatory
milieu to enhance lipid accumulation.23 Though clinical
studies of ACE inhibitors in AS have been discordant as per
currently available evidence, for lipid lowering or any
pharmacological treatment to be effective, they should be
initiated at early stages of disease.
The National Heart, lung, and blood institute conveyed a
meeting of keen investigators on CAVD, in September 2009.
The executive summary of the proceedings was published by
Rajamannan et al.24 They concluded that CAVD covers
spectrum of disease process from initial cellular changes in
valve leaﬂets to development of aortic stenosis and further
resulting in bone formation. The structure of the valve leaﬂets
is regulated by valve endothelial cells and valve interstitial cell
(VICs). VICs may behave differently at different times due to
triggering factors. The triggers for VIC differentiation or
dysfunction include factors like hemodynamic sheer stress,
solid tissue stresses, inﬂammatory cytokines, and growth
factors. Once activated, VICs can differentiate into a variety of
other cell types, including myoﬁbroblasts and osteoblasts.
Progression of disease in bicuspid aortic valves and
bioprosthetic valves may represent true model to study VIC
activation and calciﬁcation to understand the pathobiology of
CAVD. Further research is needed to study the signaling
pathway between valvular endothelial cells and VICs. Tradi-
tional echocardiography may not detect initiation and
progression of disease but molecular imaging techniques
need to be developed. Rajamannan et al.24 made recommen-
dations that studying the genetic, anatomic, and clinical risk
factors for initiation and progression of CAVD is essential to
plan therapeutic strategies.
Hypertension, smoking, diabetes mellitus, and metabolic
syndrome have been linked to the development of AS, though
the exact disease promoting action is unclear. But not all
patients with risk factors for atherosclerosis develop calciﬁc
AS and vice versa. Discrepancies exist in both conditions
(Table 1).25 In AS, large contributor of disease progression is
prominent calciﬁcation with gradual development of outﬂowobstruction whereas in coronary atherosclerosis, the events
are acute, related to plaque rupture and thrombosis. The
strategies of plaque stabilization and antithrombotic treat-
ment used for coronary atherosclerosis are not beneﬁcial for
CAVD.
3. ConclusionsThe pathophysiology of CAVD is now understood to be an
active process akin to atherosclerosis and involves initiating
factors, endothelial dysfunction, inﬂammatory responses,
oxidative stress leading to remodeling of the valves, and
mineralization of valves. The pharmacotherapeutic interven-
tions, which are likely to retard these processes, may
potentially delay the disease progression in aortic valves
and postpone need for valve replacement. Earlier is the
pharmacological intervention, better will be the expected
outcomes.
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